Brief: Hutchmed (China) Says FDA Orphan Drug Designation For Sovleplenib In Primary Immune Thrombocytopenia
29/10/2026 01:29
BRIEF-Hutchmed (China) Says FDA Orphan Drug Designation For Sovleplenib In Primary Immune Thrombocytopenia Oct 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SOVLEPLENIB IN PRIMARY IMMUNE THROMBOCYTOPENIA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation